Cochlear Americas, Englewood, Colo, has received FDA approval for its next generation Nucleus® Freedom™ cochlear implant system designed to mimic the functions of the human ear. This new system includes a wide range of programming choices, sound processors, and power options to match each individual’s unique hearing fingerprint™. The next-generation device will be available this month, and an upgrade device will be available in late summer.

“The next generation of Nucleus Freedom offers advanced implant technologies combined with a broad range of listening and wearing customization, helping our recipients experience and enjoy a natural world of sound,” says Chris Smith, president of Cochlear Americas. “The fact that this device will also be compatible and accessible to Nucleus 24 recipients is a testament to Cochlear’s lifetime commitment to support all its wearers with access to the latest technological improvements.”

Features and improvements of the device include: initial data demonstrating that Freedom is the most reliable device ever designed by any manufacturer; improved hearing performance; improved battery life and additional battery options; the Mini™ BTE Controller that provides up to 4 days of battery life; and SmartSound™ technology allows users to adapt to a range of listening environments for focused listening, comfort in noise, dynamic sound environments, and soft and distant sounds.